Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine AJ, Andreeff M. Carter BZ, et al. Among authors: mak py. Blood. 2025 Jul 3:blood.2025028935. doi: 10.1182/blood.2025028935. Online ahead of print. Blood. 2025. PMID: 40608889
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Akiyama H, et al. Among authors: mak py. Leukemia. 2024 Apr;38(4):729-740. doi: 10.1038/s41375-023-02117-2. Epub 2023 Dec 26. Leukemia. 2024. PMID: 38148395 Free PMC article.
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Nishida Y, et al. Among authors: mak py. Sci Adv. 2023 Dec;9(48):eadh1436. doi: 10.1126/sciadv.adh1436. Epub 2023 Nov 29. Sci Adv. 2023. PMID: 38019903 Free PMC article.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Carter BZ, et al. Among authors: mak py. Blood. 2023 Sep 21;142(12):1056-1070. doi: 10.1182/blood.2022019047. Blood. 2023. PMID: 37339579 Free PMC article.
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: mak py. Blood Cancer J. 2023 May 17;13(1):80. doi: 10.1038/s41408-023-00857-z. Blood Cancer J. 2023. PMID: 37193700 Free PMC article. No abstract available.
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: mak py. Blood Cancer J. 2023 Apr 24;13(1):57. doi: 10.1038/s41408-023-00830-w. Blood Cancer J. 2023. PMID: 37088806 Free PMC article.
32 results